Reply: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Documenti analoghi

• SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
  di: Nuijten, M, et al.
  Pubblicazione: (2010)
• Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
  di: Nuijten, M, et al.
  Pubblicazione: (2010)
• Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness
  di: Thompson Coon, J S, et al.
  Pubblicazione: (2009)
• Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
  di: J Thompson Coon, et al.
  Pubblicazione: (2010-01-01)
• Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
  di: Shah, Amishi Y., et al.
  Pubblicazione: (2015)